ADC Therapeutics (ADCT) Total Liabilities (2019 - 2026)

ADC Therapeutics has disclosed Total Liabilities across 8 years of filings, most recently posting $507.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $507.9 million, down 0.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.9 million (down 0.57% YoY), and the FY2025 annual result was $509.0 million, down 2.98% from the prior year.
• Total Liabilities came in at $507.9 million for Q1 2026 at ADC Therapeutics, roughly flat from $509.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $527.9 million in Q3 2025 to a low of -$28.4 million in Q1 2023.
• The 5-year median for Total Liabilities is $505.7 million (2024), against an average of $399.8 million.
• Across the five-year window, Total Liabilities decreased 8.96% in 2022 and soared 2456.1% in 2024, its largest moves.
• ADC Therapeutics' Total Liabilities stood at $411.4 million in 2022, then gained by 22.27% to $503.0 million in 2023, then grew by 4.29% to $524.6 million in 2024, then declined by 2.98% to $509.0 million in 2025, then decreased by 0.22% to $507.9 million in 2026.
• The last three Total Liabilities figures came in at $507.9 million (Q1 2026), $509.0 million (Q4 2025), and $527.9 million (Q3 2025), per Business Quant data.